Magic mushroom compound tested for Tough-to-Treat OCD

NCT ID NCT04882839

Recruiting now Symptom relief Sponsor: Beersheva Mental Health Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a drug called psilocybin, given alongside talk therapy, can help people with severe obsessive-compulsive disorder (OCD) who haven't gotten better with standard treatments. Fifteen adults will receive three eight-hour sessions under the influence of psilocybin, plus 12 therapy sessions. Researchers will measure changes in OCD symptoms, anxiety, and depression to see if the approach is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could point toward a new treatment option for people with severe OCD who haven't been helped by standard therapies.
What could go wrong: This is a very small early-phase trial with only 15 people, so results may not apply to everyone. Psilocybin can cause intense psychological experiences and side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSESSIVE-COMPULSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obsessive-compulsive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBSESSIVE-COMPULSIVE DISORDER

Contacts and locations

Locations

Beer Sheva Mental Health Center
RECRUITING

Beersheba, 8461144, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.